^
    Back
    Association details:
    Biomarker:ERBB3 expression
    Cancer:Bladder Cancer
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    AACR-II 2020
    Title:

    Abstract LB-326: The role of HER3 in HER2-amplified cancers other than breast cancers

    Published date:
    05/15/2020
    Excerpt:
    Lapatinib induced apoptosis correlated with HER3 activation. Tumor growth was reduced upon HER3 knockdown in HER2-amplified cancers other than breast cancers, particularly cancers with constitutive HER3 phosphorylation. Many HER2-amplified cancers of the breast (HCC1569, HCC1954, HCC1419, UACC732, SUM190), bladder (CLS-439), stomach (N87, OE19), esophagus (TE4, KYSE410), lung (Calu3), and endometrium (USPC-ARC1, USPC-ARC2) showed HER3 activation...
    DOI:
    10.1158/1538-7445.AM2020-LB-326